Moleculight Corporation

Wound Care Solutions. Maker-MolecuLight i:X handheld wound imaging device for clinicians.

Based in PA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $140K in lobbying spend across 5 quarterly filings, Moleculight Corporation is an active lobbying client. Their lobbying covers 1 issue area.

$140K
Total Spend
1
Years Active
1
Firms Hired
4
Lobbyists Deployed
1
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2025$140K

Issues Lobbied

Medicare/Medicaid

Lobbying Firms

King & Spalding LLP

Lobbyists

Scott DziengelskiDavid FarberJulia RichardsonKendrick Meek

Government Agencies Targeted

These are the government entities that Moleculight Corporation disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATEFederal Emergency Management Agency (FEMA)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid

Medicare Coverage Issues.

Lobbying on Medicare coverage issues

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

Select Medical Holdings Corporation
$22.2M total spend
Highmark INC
$8.8M total spend
Spark Therapeutics, INC.
$6.2M total spend
Trustees of the University of Pennsylvania
$4.7M total spend
Select Medical Corporation
$4.5M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.